(unlicensed indication) Approved for gastroenterology use only.
For hyperbilirubinaemia, as a second line option where colestyramine is not tolerated
Second line option when statins not tolerated. Prescribe generically.
2nd line agent. Atorvastatin 1st line.
2nd line after atorvastatin.
Current evidence suggests that patient should be treated with not less than 40mg daily for secondary prevention of ischemic events [unless prescribed an interacting drug]
Consultant lipidologist initiation for refractory hypertriglyceridaemia.
See Herefordshire LPT except following consultant lipidologist initiation for refractory hypertriglyceridaemia. Low Value Medicine
Lack of clinical and cost effectiveness
Traffic Light Status Information